CB1 blocker reversed anxiety from stress hormones and cocaine withdrawal in rats
In rats, the CB1 antagonist AM251 reversed anxiety caused by the stress hormone CRF and by cocaine withdrawal, suggesting the endocannabinoid system mediates stress-related anxiety through non-HPA pathways.
Quick Facts
What This Study Found
Researchers tested whether blocking CB1 receptors could reduce anxiety caused by two different triggers: direct brain injection of corticotropin-releasing factor (CRF, the brain's primary stress peptide) and withdrawal from 14 days of cocaine.
AM251 reversed anxiety from both CRF and cocaine withdrawal in a dose-dependent manner when injected directly into the brain. At its highest dose alone (without CRF or cocaine), AM251 actually increased anxiety, showing dual effects depending on context.
Importantly, AM251 increased plasma corticosterone (the rat stress hormone) regardless of CRF treatment or cocaine history, suggesting the anxiolytic effect worked through brain mechanisms independent of the hormonal stress axis (HPA).
Key Numbers
AM251 200 micrograms alone: anxiogenic. AM251 10-100 micrograms: reversed CRF-induced and cocaine withdrawal anxiety dose-dependently. Corticosterone elevated by AM251 regardless of other treatments.
How They Did This
Two experiments in male rats using elevated plus maze for anxiety measurement. Experiment 1: AM251 (0, 10, 100, 200 micrograms, i.c.v.) before CRF (0.5 micrograms, i.c.v.). Experiment 2: 14 days cocaine (20 mg/kg), then 48-hour withdrawal with AM251 pretreatment. Plasma corticosterone measured after behavioral testing.
Why This Research Matters
The finding that CB1 blockade can both cause and relieve anxiety depending on dose and context resolved an apparent contradiction in the literature. It also identified endocannabinoid signaling as a mediator of stress peptide effects, independent of the hormonal stress response.
The Bigger Picture
This study provided a mechanistic link between the endocannabinoid and stress systems that could explain why cannabis is commonly used for anxiety despite sometimes causing it. The dose-dependent dual effect mirrors the common human experience where small amounts reduce anxiety but large amounts increase it.
What This Study Doesn't Tell Us
Central (brain) administration of AM251 does not reflect oral drug delivery. Rat anxiety measures are behavioral proxies. Only male rats tested. The high dose anxiogenic effect limits therapeutic window.
Questions This Raises
- ?Could targeted endocannabinoid modulation treat withdrawal anxiety in cocaine users?
- ?Is the dose-dependent anxiety effect relevant to clinical cannabis use?
- ?Can CRF-endocannabinoid interactions be targeted without affecting the HPA axis?
Trust & Context
- Key Stat:
- Same drug caused or relieved anxiety depending on dose and context
- Evidence Grade:
- Animal pharmacology study with clear dose-response and mechanistic dissection. Strong internal validity but limited clinical translation.
- Study Age:
- Published in 2012. CRF-endocannabinoid interactions remain an active area of stress neuroscience research.
- Original Title:
- Antagonism of cannabinoid 1 receptors reverses the anxiety-like behavior induced by central injections of corticotropin-releasing factor and cocaine withdrawal.
- Published In:
- Neuroscience, 204, 125-33 (2012)
- Authors:
- Kupferschmidt, D A, Newman, A E, Boonstra, R, Erb, S
- Database ID:
- RTHC-00577
Evidence Hierarchy
Tests effects in animals (usually mice or rats), not humans.
What do these levels mean? →Frequently Asked Questions
Can the cannabinoid system both cause and reduce anxiety?
Yes. In this study, a high dose of a CB1 blocker increased anxiety on its own, but lower doses of the same drug reversed anxiety caused by stress hormones or cocaine withdrawal. This dose-dependent duality may explain why cannabis can both relieve and cause anxiety in people.
What does this mean for treating withdrawal anxiety?
The finding that endocannabinoid signaling mediates cocaine withdrawal anxiety opens possibilities for cannabinoid-based treatments. However, the narrow therapeutic window (too much causes anxiety, the right amount relieves it) makes dosing critical.
Read More on RethinkTHC
- anxiety-leaving-house-weed-withdrawal-agoraphobia
- anxiety-response-technique-weed-withdrawal
- anxiety-toolkit-weed-withdrawal
- anxiety-worse-after-quitting-weed
- breathing-exercises-weed-withdrawal-anxiety
- cannabis-induced-anxiety
- does-weed-help-anxiety
- grounding-techniques-weed-withdrawal
- health-anxiety-weed-withdrawal
- manage-anxiety-without-weed
- quitting-weed-anxiety-disorder
- quitting-weed-anxiety-medication-ssri
- self-medicating-anxiety-with-weed
- therapy-quitting-weed-anxiety
- weed-and-anxiety
- weed-biphasic-effect-anxiety
- weed-generalized-anxiety-disorder
- weed-panic-attacks
- weed-paranoia
- weed-social-anxiety
- weed-tolerance-anxiety-stopped-working
- weed-withdrawal-anxiety
- weed-withdrawal-panic-attacks-night
- weed-withdrawal-work-anxiety
- withdrawal-anxiety-vs-real-anxiety
- why-does-weed-make-you-paranoid-amygdala
- why-weed-makes-me-anxious-now-not-before
- thc-and-benzodiazepines-dangerous-overlap
- thc-and-antibiotics-safe-cannabis-while-on
- thc-and-diabetes-medication-blood-sugar
- cannabis-and-socializing-only-use-around-others
Cite This Study
https://rethinkthc.com/research/RTHC-00577APA
Kupferschmidt, D A; Newman, A E; Boonstra, R; Erb, S. (2012). Antagonism of cannabinoid 1 receptors reverses the anxiety-like behavior induced by central injections of corticotropin-releasing factor and cocaine withdrawal.. Neuroscience, 204, 125-33. https://doi.org/10.1016/j.neuroscience.2011.07.022
MLA
Kupferschmidt, D A, et al. "Antagonism of cannabinoid 1 receptors reverses the anxiety-like behavior induced by central injections of corticotropin-releasing factor and cocaine withdrawal.." Neuroscience, 2012. https://doi.org/10.1016/j.neuroscience.2011.07.022
RethinkTHC
RethinkTHC Research Database. "Antagonism of cannabinoid 1 receptors reverses the anxiety-l..." RTHC-00577. Retrieved from https://rethinkthc.com/research/kupferschmidt-2012-antagonism-of-cannabinoid-1
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkTHC research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.